x
Filter:
Filters applied
- Clinical Practice Guidelines and Recommendations
- LDL-CRemove LDL-C filter
- coronary artery calciumRemove coronary artery calcium filter
Publication Date
Please choose a date range between 2014 and 2021.
Author
- Blumenthal, Roger S2
- Kopecky, Stephen L2
- Lopez-Jimenez, Francisco2
- Allison, Thomas G1
- Arruda-Olson, Adelaide M1
- Blaha, Michael J1
- Braun, Lynne T1
- Cainzos-Achirica, Miguel1
- Desai, Chintan S1
- Grundy, Scott M1
- Hayes, Sharonne N1
- Heidenreich, Paul A1
- Hurst, R Todd1
- Kullo, Iftikhar J1
- Lloyd-Jones, Donald1
- Martin, Seth S1
- Mulvagh, Sharon L1
- Orringer, Carl E1
- Pollak, Amy W1
- Saseen, Joseph J1
- Smith, Sidney C Jr1
- Sperling, Laurence S1
- Stone, Neil J1
- Thomas, Randal J1
- Trejo-Gutierrez, Jorge F1
Keyword
- ASCVD3
- atherosclerotic cardiovascular disease3
- CAC3
- low-density lipoprotein cholesterol3
- Adult Treatment Panel III2
- CHD2
- ABI1
- ACC1
- ACC/AHA1
- AHA1
- AHA/ACC/MS1
- American College of Cardiology1
- American College of Cardiology/American Heart Association1
- American Heart Association1
- American Heart Association/American College of Cardiology/multisociety1
- ATP III1
- ATP-III1
- CCA1
- CVD1
- DM1
- Framingham Risk Score1
- FRS1
- HR1
Clinical Practice Guidelines and Recommendations
3 Results
- Consensus recommendation
High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better
Mayo Clinic ProceedingsVol. 96Issue 10p2660–2670Published online: September 14, 2021- Scott M. Grundy
- Neil J. Stone
- Roger S. Blumenthal
- Lynne T. Braun
- Paul A. Heidenreich
- Donald Lloyd-Jones
- and others
Cited in Scopus: 4Review of the US and European literature indicates that most patients at high risk for atherosclerotic cardiovascular disease (ASCVD are not treated with high-intensity statins, despite strong clinical-trial evidence of maximal statin benefit. High-intensity statins are recommended for 2 categories of patients: those with ASCVD (secondary prevention) and high-risk patients without clinical ASCVD. Most patients with ASCVD are candidates for high-intensity statins, with a goal for low-density lipoprotein cholesterol reduction of 50% or greater. - Review
Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines
Mayo Clinic ProceedingsVol. 90Issue 9p1262–1271Published online: August 11, 2015- Miguel Cainzos-Achirica
- Chintan S. Desai
- Libin Wang
- Michael J. Blaha
- Francisco Lopez-Jimenez
- Stephen L. Kopecky
- and others
Cited in Scopus: 16The 2013 American College of Cardiology/American Heart Association cardiovascular disease prevention guidelines represent an important step forward in the risk assessment and management of atherosclerotic cardiovascular disease in clinical practice. Differentiated risk prediction equations for women and black individuals were developed, and convenient 10-year and lifetime risk assessment tools were provided, facilitating their implementation. Lifestyle modification was portrayed as the foundation of preventive therapy. - Special article
A Perspective on the New American College of Cardiology/American Heart Association Guidelines for Cardiovascular Risk Assessment
Mayo Clinic ProceedingsVol. 89Issue 9p1244–1256Published online: August 13, 2014- Iftikhar J. Kullo
- Jorge F. Trejo-Gutierrez
- Francisco Lopez-Jimenez
- Randal J. Thomas
- Thomas G. Allison
- Sharon L. Mulvagh
- and others
Cited in Scopus: 18The recently published American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for cardiovascular risk assessment provide equations to estimate the 10-year and lifetime atherosclerotic cardiovascular disease (ASCVD) risk in African Americans and non-Hispanic whites, include stroke as an adverse cardiovascular outcome, and emphasize shared decision making. The guidelines provide a valuable framework that can be adapted on the basis of clinical judgment and individual/institutional expertise.